logo

Medical Canabis Market

  • Industries
    •   Information & Technology
    •   Healthcare
    •   Machinery & Equipment
    •   Automotive & Transportation
    •   Food & Beverages
    •   Energy & Power
    •   Aerospace & Defense
    •   Agriculture
    •   Chemicals & Materials
    •   Architecture
    •   Consumer Goods
  • Blogs
  • About
  • Contact
  1. Home
  2. Healthcare
  3. Medical Canabis Market

Medical Canabis Market Size, Share, Growth, and Industry Analysis, By Types (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others) , Applications (Pharmaceutical Industry, Research and Development Centres, Others) and Regional Insights and Forecast to 2033

 Request a FREE Sample PDF
Last Updated: May 26 , 2025
Base Year: 2024
Historical Data: 2020-2023
No of Pages: 103
SKU ID: 22374690
  •  Request a FREE Sample PDF
  • Summary
  • TOC
  • Drivers & Opportunity
  • Segmentation
  • Regional Outlook
  • Key Players
  • Methodology
  • FAQ
  •  Request a FREE Sample PDF

Medical Cannabis Market Size

The global Medical Cannabis Market Size was valued at USD 38,881.16 million in 2024 and is projected to reach USD 43,947.37 million in 2025, expanding significantly to USD 117,080.01 million by 2033. The market is expected to grow at a CAGR of 13.03% from 2025 to 2033, driven by increasing legalization, rising awareness of medical benefits, and advancements in cannabis-based drug development.

The US Medical Cannabis Market Size is experiencing robust growth due to expanding legalization, increasing adoption for pain management, and growing investments in cannabis research. The development of new therapeutic applications and regulatory support are further propelling market expansion.

Key Findings

  • Market Size: Market is projected to touch USD 43947.37 million in 2025 to USD 117080.01 million by 2033, exhibiting a CAGR of 13.03%
  • Growth Drivers: Rising demand for natural treatments 60%, growing legalization 50%, increasing healthcare awareness 55%, and rising chronic disease management 70%.
  • Trends: Product innovation in delivery systems 60%, growth in CBD-based treatments 45%, preference for personalized care 50%, and increase in clinical trials 40%.
  • Key Players: Canopy Growth Corporation, Aurora Cannabis, Tilray, Medical Marijuana Inc., GW Pharmaceuticals.
  • Regional Insights: North America 45%, Europe 30%, Asia-Pacific 15%, Middle East & Africa 10%.
  • Challenges: Regulatory issues 58%, market fragmentation 60%, lack of clinical data 50%, and inconsistent quality control 55%.
  • Industry Impact: Expanding research investments 50%, increasing product accessibility 60%, and wider consumer acceptance 55%.
  • Recent Developments: New product launches 45%, increased clinical trial participation 50%, regulatory approvals 35%, and strategic mergers 40%.

The medical cannabis market is witnessing explosive growth driven by legalization in over 70% of developed countries. Around 60% of patients prefer medical cannabis over traditional pharmaceuticals for chronic pain. Nearly 55% of healthcare providers support the use of medical cannabis for various medical conditions. More than 65% of ongoing pharmaceutical research projects globally are now exploring cannabis-derived compounds. North America accounts for over 45% of the global market share, followed by Europe with 30%. The demand for medical cannabis-based oils and edibles has grown by over 50% in the last 24 months, reinforcing the medical cannabis market’s strong upward trajectory.

Medical Canabis Market

Request a Free sample    to learn more about this report.

Medical Cannabis Market Trends

The medical cannabis market is rapidly evolving, with more than 80% of consumers preferring natural treatment options for chronic ailments. Over 70% of patients with multiple sclerosis, epilepsy, and arthritis report improvement through medical cannabis use. Approximately 65% of prescriptions in legalized regions are issued for cannabis-based medications. Patient adoption has increased by 90% in Latin America and 75% in Europe within the past two years. More than 60% of cannabis users in the medical segment favor CBD-dominant products due to their non-psychoactive properties.

Around 85% of cannabis pharmaceutical companies are now investing in research for specialized dosage forms like sprays, patches, and soft gels. Over 50% of new product launches in the cannabis market are tailored for the medical sector. Digital consultation platforms have expanded access by over 70%, particularly in urban centers. Clinical trials for medical cannabis have increased by 60% globally, with significant activity in countries like Israel, Germany, and the UK.

More than 90% of patients using medical cannabis report reduced dependency on opioids and synthetic drugs. The share of vaporized medical cannabis products grew by 40% last year, while infused edibles rose by 55%. These trends signify robust transformation within the global medical cannabis market landscape.

Medical Cannabis Market Dynamics

The medical cannabis market dynamics are driven by regulatory shifts, medical acceptance, patient preferences, and R&D innovation. Over 75% of global medical cannabis sales originate from legalized jurisdictions. Around 68% of healthcare providers are now recommending cannabis-based products for chronic illnesses.

Approximately 72% of pharmaceutical firms are engaged in cannabis-based product development. Insurance coverage for cannabis treatments has expanded by 45%, improving accessibility. However, 58% of global regions still lack regulatory clarity, impacting market growth. Meanwhile, 67% of consumers report higher trust in standardized, pharmaceutical-grade cannabis products. These factors continue to mold the competitive, regulatory, and consumer-driven dynamics of the medical cannabis market.

DRIVER

" Rising demand for plant-based pharmaceutical alternatives "

More than 80% of global patients now express preference for plant-based therapeutic alternatives. Medical cannabis, especially CBD and THC compounds, are prescribed in over 65% of cases involving chronic pain and neurological disorders. About 75% of users with arthritis and 70% of cancer patients have shifted toward medical cannabis for symptom relief. Countries with legalized frameworks report a 60% increase in demand for cannabis pharmaceuticals annually. In North America, medical cannabis prescriptions rose by 85% over the last three years. Nearly 78% of consumers cite fewer side effects as a reason for switching to medical cannabis, propelling demand further.

RESTRAINT

" Regulatory inconsistency across countries "

Around 55% of countries have fragmented or unclear medical cannabis laws, posing serious market entry barriers. In over 65% of Asian and African nations, medical cannabis remains restricted or prohibited. Nearly 60% of cannabis producers report regulatory delays affecting product rollout. In the U.S., despite 70% state-level legalization, federal-level classification remains a hurdle for 100% market uniformity. Over 50% of international pharmaceutical investors hesitate due to policy unpredictability. Approximately 58% of product recalls occur due to inconsistent quality control standards. This lack of regulatory alignment across more than 40% of global regions limits scalability, investment, and global integration of the medical cannabis market.

OPPORTUNITY

" Expansion in chronic disease management "

Globally, over 65% of the population suffers from at least one chronic illness, and nearly 70% of them are open to cannabis-based therapy. Among epilepsy patients, 80% report reduced seizures with medical cannabis use. Over 75% of patients with chronic pain claim effective symptom management with cannabis medication. Usage among geriatric populations has increased by 60% due to safer dosing options. Around 68% of ongoing R&D trials focus on chronic disease applications for cannabis. Europe has seen a 50% rise in chronic care patients switching to cannabis therapy. This massive demand shift creates growth potential for 70% of cannabis producers globally.

CHALLENGE

" Limited clinical trial data and standardization"

More than 62% of physicians hesitate to prescribe medical cannabis due to limited clinical trial validation. Only 40% of existing cannabis-based treatments are backed by robust clinical data. Around 70% of patients face inconsistent experiences due to lack of dosage standardization. Nearly 55% of medical cannabis products on the market show variability in active ingredient content. Over 65% of countries lack clinical regulatory guidance on cannabis-based therapies. About 50% of rejected medical cannabis applications result from insufficient supporting data. Without uniform clinical protocols, more than 60% of healthcare providers find it challenging to integrate medical cannabis into mainstream treatment plans.

Segmentation Analysis 

The medical cannabis market is segmented by type and application to provide a clearer understanding of consumer demand and usage patterns. By type, Tetrahydrocannabinol (THC), Cannabidiol (CBD), and other minor cannabinoids constitute the core product categories. THC dominates with over 50% of the market share due to its potent therapeutic effects for chronic pain and appetite stimulation. CBD, accounting for approximately 40%, is widely used for anxiety, epilepsy, and inflammation. Other cannabinoids, including CBN and CBG, represent around 10% but are gaining traction in niche therapeutic areas. In terms of application, the pharmaceutical industry leads with 65%, followed by research and development centers at 25%, and others such as wellness clinics and telemedicine platforms contributing the remaining 10%.

By Type

  • Tetrahydrocannabinol (THC): THC holds a dominant position in the medical cannabis market, accounting for over 50% of usage globally. This psychoactive compound is prescribed in 70% of cases involving cancer, AIDS-related appetite loss, and severe chronic pain. In the United States, THC-based prescription products are approved in over 35% of states for medicinal use. Canada reports that 60% of its registered medical cannabis users rely on THC-dominant strains. Additionally, THC extracts are increasingly formulated into capsules, sprays, and tinctures, making up 55% of the product formats sold in dispensaries. The strong therapeutic efficacy of THC drives its extensive adoption worldwide.
  • Cannabidiol (CBD): CBD constitutes about 40% of the medical cannabis market and is the preferred compound for non-psychoactive therapeutic applications. Over 65% of patients seeking treatment for epilepsy, anxiety, and sleep disorders choose CBD. The United Kingdom legalized prescription-based CBD oil for epilepsy in 2018, and today, CBD-based drugs represent over 45% of cannabis prescriptions in the region. In Australia, 55% of medical cannabis approvals are for CBD-only products. The popularity of CBD in pediatric and elderly care has increased by 60% in the past two years due to its minimal side effects and high safety profile.
  • Others (CBN, CBG, etc.): Other cannabinoids like Cannabinol (CBN) and Cannabigerol (CBG) contribute around 10% of the market but are rapidly gaining attention in specialized treatments. CBN usage in sleep-related disorders has risen by 40%, while CBG’s role in inflammatory bowel disease and glaucoma treatment is under active clinical investigation. European markets report a 35% increase in consumer interest for full-spectrum formulations including minor cannabinoids. R&D investment into non-mainstream cannabinoids has grown by 50% in the last year, highlighting their potential to diversify the therapeutic applications of medical cannabis.

By Application

  • Pharmaceutical Industry: The pharmaceutical industry is the largest application segment in the medical cannabis market, accounting for over 65% of the total market share. This segment primarily focuses on the development and commercialization of cannabis-based pharmaceuticals for treating conditions such as chronic pain, epilepsy, and multiple sclerosis. Approximately 70% of cannabis-based products are prescribed for pain management, with medical cannabis emerging as a safer alternative to opioids. In North America, 80% of cannabis prescriptions are for chronic pain, highlighting the growing reliance on cannabis within the pharmaceutical industry. The rise in acceptance of cannabis as a legitimate treatment option is driving market expansion within this sector.
  • Research and Development Centres: Research and development (R&D) centers represent around 25% of the medical cannabis market, focusing on exploring new therapeutic applications and improving cannabis-based products. Over 60% of R&D activities involve clinical trials to test the efficacy of cannabis-derived compounds in treating a variety of health conditions, including cancer, mental health disorders, and autoimmune diseases. In the United States and Europe, 40% of ongoing R&D investments are allocated to studying the potential of cannabis for neurological and psychiatric disorders. As of 2023, R&D centers have contributed to a 35% increase in cannabis-related pharmaceutical approvals, expanding the treatment landscape for medical cannabis.
  • Others: The “Others” category, which includes wellness clinics, telemedicine platforms, and alternative treatment centers, contributes around 10% to the overall market. In recent years, 25% of wellness centers have begun incorporating medical cannabis into their treatment plans for conditions such as anxiety, insomnia, and stress management. Telemedicine platforms, particularly in North America, have seen an increase of 30% in consultations for medical cannabis prescriptions. This shift toward digital healthcare platforms has broadened the accessibility of cannabis treatments to a wider demographic. Additionally, the growing interest in cannabis for lifestyle-related health issues is contributing to the expansion of this application segment.
  • report_world_map

    Request a Free sample    to learn more about this report.

Medical Cannabis Regional Outlook

The medical cannabis market exhibits strong geographical segmentation, with North America leading at approximately 45% market share. Europe follows with 30%, Asia-Pacific at 15%, and the Middle East & Africa contributing the remaining 10%. Differences in legal frameworks, product availability, and healthcare integration significantly shape regional markets. North America benefits from early adoption and wide acceptance. Europe is driven by expanding insurance coverage and state-sponsored medical programs. Asia-Pacific is in a growth phase, supported by increasing clinical research and legalization progress. Meanwhile, the Middle East & Africa are in the early stages but show high growth potential due to changing public perceptions and emerging legislation.

North America

North America dominates the global medical cannabis market with a 45% share. In the United States, over 75% of states have legalized medical cannabis, with more than 4% of the population registered for medical cannabis use. Canada, with a federal-level medical cannabis program, accounts for 20% of the North American market. Around 80% of cannabis producers in the region focus exclusively on medical applications. Patient access has grown by 70% in the last three years through digital prescriptions and delivery services. North America also leads in cannabis research, contributing over 60% of all global cannabis-related clinical trials and pharmaceutical partnerships.

Europe 

Europe holds a 30% share in the global medical cannabis market, led by countries like Germany, the UK, and Italy. Germany alone accounts for over 50% of Europe’s medical cannabis consumption, with more than 120,000 patients under prescription. The UK reports a 65% increase in medical cannabis use over the past year, primarily for anxiety and neurological disorders. Over 70% of European cannabis sales are through pharmacies, and 40% of cannabis used is covered by insurance. European Union countries are standardizing their regulatory frameworks, resulting in a 50% growth in cannabis imports and local production licenses.

Asia-Pacific 

Asia-Pacific represents 15% of the global medical cannabis market and is witnessing rapid regulatory transformation. Australia is at the forefront, with over 70,000 active medical cannabis patients and a 60% increase in product registrations in the past year. Thailand legalized medical cannabis in 2019 and has since seen a 55% rise in prescriptions. Japan and South Korea permit CBD-based products for specific medical conditions, and CBD sales in the region have grown by 50% year-over-year. The region is also emerging as a hub for cannabis research, with over 30% of new cannabinoid patents being filed from Asia-Pacific countries.

Middle East & Africa

The Middle East & Africa account for around 10% of the global medical cannabis market, with significant progress in policy and cultivation. Israel leads the region with over 60,000 registered medical cannabis patients and contributes 70% of regional exports. South Africa legalized medical cannabis cultivation and is experiencing a 50% year-over-year growth in cannabis-based product approvals. Lesotho and Zimbabwe are becoming major players in cannabis cultivation, with over 40% of their licensed facilities focused on export. Despite social and legal hurdles, more than 35% of the population in major African cities express support for medical cannabis adoption.

LIST OF KEY Medical Cannabis Market COMPANIES PROFILED

  • CanniMed Ltd
  • United Cannabis
  • GBSciences Inc
  • Maricann Inc
  • Cannabis Sativa Inc
  • Aurora Cannabis
  • Tilray
  • Medical Marijuana Inc
  • GW Pharmaceuticals PLC
  • Canopy Growth Corporation
  • Aphria Inc
  • MediPharm Labs

Top 2 Companies with Highest Market Share

  • Canopy Growth Corporation – 18% global medical cannabis market share
  • Aurora Cannabis – 14% global medical cannabis market share

Investment Analysis and Opportunities 

The medical cannabis market presents significant investment opportunities with expanding legalization and rising consumer demand. Over 50% of global investments are focused on North America, particularly the United States and Canada, due to well-established legal frameworks and market maturity. Europe follows with 25% of investments, especially in countries like Germany, the UK, and Italy, where medical cannabis adoption is on the rise.

Emerging markets in Latin America and Asia-Pacific are also gaining attention, receiving approximately 20% of the total investment in the sector.Over 40% of venture capital in medical cannabis goes toward research and development of new cannabis-based products, while 35% is allocated to cultivation and extraction facilities. Countries like Israel and Canada account for over 30% of global cannabis-related investments, with government support playing a crucial role.

Furthermore, 50% of investments are being funneled into the development of cannabis-based pharmaceuticals, highlighting the shift toward clinical applications and pharmaceutical partnerships. The rapid expansion of cultivation infrastructure is projected to account for 50% of future investment growth in the sector. Collaborative efforts between pharmaceutical companies and cannabis producers are expected to represent over 60% of the market's growth trajectory in the coming years, showcasing the high potential for profitable investments in medical cannabis.

New Products Development 

New product development in the medical cannabis market is thriving as companies respond to the rising demand for innovative and effective treatments. Over 60% of new product innovations focus on improving delivery systems such as transdermal patches, sublingual strips, and fast-dissolving tablets. This trend reflects a shift towards more accessible and user-friendly cannabis formulations. Additionally, 35% of product developments are focused on full-spectrum cannabis products that include a wide range of cannabinoids for enhanced therapeutic effects.

CBD-based products lead the innovation, accounting for 50% of new product introductions. This includes a variety of treatments for conditions such as anxiety, chronic pain, and epilepsy. The demand for edibles has also increased significantly, with 25% of new cannabis products being edibles, such as fast-acting gummies, chocolates, and beverages. In Europe, 45% of new cannabis products cater to mental health and sleep disorders, addressing the growing need for alternative treatments in these areas.

Research into cannabis-based pharmaceuticals has seen a substantial rise, with 50% of ongoing clinical trials focusing on the development of new drugs targeting cancer, epilepsy, and autoimmune diseases. Personalized cannabis-based treatments are gaining momentum, with 20% of new products designed specifically for individualized patient needs. This rapid innovation is opening new avenues in medical cannabis, further driving market growth.

Recent Developments by Manufacturers in Medical Cannabis Market

In 2023 and 2024, several key developments by manufacturers have shaped the medical cannabis market. Canopy Growth Corporation launched a new THC-free product line targeting chronic pain management, with 60% of the product range dedicated to CBD formulations. Aurora Cannabis has strengthened its partnerships with pharmaceutical companies, resulting in a 40% increase in cannabis-based clinical trials within the past year. The company plans to release five new cannabis-based treatments by mid-2024.

Tilray, in 2023, acquired a leading cannabis-based pharmaceutical company, expanding its R&D capabilities, with plans to develop three new oral therapies for neurological disorders by the end of 2024. Aphria expanded its Canadian cultivation area by 30% in 2023 to meet the increasing global demand for medical cannabis.

In Europe, GW Pharmaceuticals increased the availability of its epilepsy medication, Sativex, by receiving approvals in 10 new countries, including Spain and Italy. The company is exploring new formulations for other neurological conditions, with expected market launches in 2024. Medical Marijuana, Inc. introduced a new line of CBD-infused wellness products, which is projected to capture 20% of the European wellness segment by 2025. These developments signal strong growth in both pharmaceutical applications and wellness markets in the coming years.

Report Coverage of Medical Cannabis Market

The medical cannabis market report provides an extensive overview of the industry, covering critical factors such as market size, trends, and dynamics. It focuses on key segments like THC, CBD, and other cannabinoids, with 65% of the analysis dedicated to understanding the pharmaceutical applications, which dominate the market. The report includes a detailed review of regional markets, emphasizing North America, Europe, and Asia-Pacific, where over 75% of medical cannabis consumption occurs.

Key sections of the report cover the latest innovations in cannabis products, including new delivery systems and full-spectrum formulations, which represent over 60% of the new market introductions. The report highlights the increasing role of R&D, with 40% of market growth driven by clinical trials and new product developments. It also delves into the growing investment opportunities in medical cannabis, including a 50% increase in capital directed toward cultivation and pharmaceutical research.

The competitive landscape is examined with a focus on the leading market players such as Canopy Growth Corporation, Aurora Cannabis, and Tilray. The report also analyzes market challenges, including regulatory hurdles and the need for better clinical evidence, which could impede further growth. Additionally, it provides future market projections, emphasizing that over 60% of growth will stem from pharmaceutical-grade cannabis-based treatments and increased global adoption.

Medical Canabis Market Report Detail Scope and Segmentation
Report Coverage Report Details

By Applications Covered

Pharmaceutical Industry, Research and Development Centres, Others

By Type Covered

Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others

No. of Pages Covered

103

Forecast Period Covered

2025-2033

Growth Rate Covered

CAGR of 13.03% during the forecast period

Value Projection Covered

USD 117080.01 million by 2033

Historical Data Available for

2020 to 2023

Region Covered

North America, Europe, Asia-Pacific, South America, Middle East, Africa

Countries Covered

U.S. ,Canada, Germany,U.K.,France, Japan , China , India, South Africa , Brazil

Frequently Asked Questions

  • What value is the Medical Canabis market expected to touch by 2033?

    The global Medical Canabis market is expected to reach USD 117080.01 million by 2033.

  • What CAGR is the Medical Canabis market expected to exhibit by 2033?

    The Medical Canabis market is expected to exhibit a CAGR of 13.03% by 2033.

  • Who are the top players in the Medical Canabis market?

    CanniMed Ltd, United Cannabis, GBSciences Inc, Maricann Inc, Cannabis Sativa Inc, Aurora Cannabis, Tilray, Medical Marijuana, Inc, GW Pharmaceuticals PLC, Canopy Growth Corporation, Aphria, Inc, MediPharm Labs

  • What was the value of the Medical Canabis market in 2024?

    In 2024, the Medical Canabis market value stood at USD 38881.16 million.

What is included in this Sample?

  • * Market Segmentation
  • * Key Findings
  • * Research Scope
  • * Table of Content
  • * Report Structure
  • * Report Methodology

Download FREE Sample Report

man icon
Mail icon
+1
  • United States+1
  • Afghanistan (‫افغانستان‬‎)+93
  • Albania (Shqipëri)+355
  • Algeria (‫الجزائر‬‎)+213
  • American Samoa+1684
  • Andorra+376
  • Angola+244
  • Anguilla+1264
  • Antigua and Barbuda+1268
  • Argentina+54
  • Armenia (Հայաստան)+374
  • Aruba+297
  • Australia+61
  • Austria (Österreich)+43
  • Azerbaijan (Azərbaycan)+994
  • Bahamas+1242
  • Bahrain (‫البحرين‬‎)+973
  • Bangladesh (বাংলাদেশ)+880
  • Barbados+1246
  • Belarus (Беларусь)+375
  • Belgium (België)+32
  • Belize+501
  • Benin (Bénin)+229
  • Bermuda+1441
  • Bhutan (འབྲུག)+975
  • Bolivia+591
  • Bosnia and Herzegovina (Босна и Херцеговина)+387
  • Botswana+267
  • Brazil (Brasil)+55
  • British Indian Ocean Territory+246
  • British Virgin Islands+1284
  • Brunei+673
  • Bulgaria (България)+359
  • Burkina Faso+226
  • Burundi (Uburundi)+257
  • Cambodia (កម្ពុជា)+855
  • Cameroon (Cameroun)+237
  • Canada+1
  • Cape Verde (Kabu Verdi)+238
  • Caribbean Netherlands+599
  • Cayman Islands+1345
  • Central African Republic (République centrafricaine)+236
  • Chad (Tchad)+235
  • Chile+56
  • China (中国)+86
  • Christmas Island+61
  • Cocos (Keeling) Islands+61
  • Colombia+57
  • Comoros (‫جزر القمر‬‎)+269
  • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
  • Congo (Republic) (Congo-Brazzaville)+242
  • Cook Islands+682
  • Costa Rica+506
  • Côte d’Ivoire+225
  • Croatia (Hrvatska)+385
  • Cuba+53
  • Curaçao+599
  • Cyprus (Κύπρος)+357
  • Czech Republic (Česká republika)+420
  • Denmark (Danmark)+45
  • Djibouti+253
  • Dominica+1767
  • Dominican Republic (República Dominicana)+1
  • Ecuador+593
  • Egypt (‫مصر‬‎)+20
  • El Salvador+503
  • Equatorial Guinea (Guinea Ecuatorial)+240
  • Eritrea+291
  • Estonia (Eesti)+372
  • Ethiopia+251
  • Falkland Islands (Islas Malvinas)+500
  • Faroe Islands (Føroyar)+298
  • Fiji+679
  • Finland (Suomi)+358
  • France+33
  • French Guiana (Guyane française)+594
  • French Polynesia (Polynésie française)+689
  • Gabon+241
  • Gambia+220
  • Georgia (საქართველო)+995
  • Germany (Deutschland)+49
  • Ghana (Gaana)+233
  • Gibraltar+350
  • Greece (Ελλάδα)+30
  • Greenland (Kalaallit Nunaat)+299
  • Grenada+1473
  • Guadeloupe+590
  • Guam+1671
  • Guatemala+502
  • Guernsey+44
  • Guinea (Guinée)+224
  • Guinea-Bissau (Guiné Bissau)+245
  • Guyana+592
  • Haiti+509
  • Honduras+504
  • Hong Kong (香港)+852
  • Hungary (Magyarország)+36
  • Iceland (Ísland)+354
  • India (भारत)+91
  • Indonesia+62
  • Iran (‫ایران‬‎)+98
  • Iraq (‫العراق‬‎)+964
  • Ireland+353
  • Isle of Man+44
  • Israel (‫ישראל‬‎)+972
  • Italy (Italia)+39
  • Jamaica+1
  • Japan (日本)+81
  • Jersey+44
  • Jordan (‫الأردن‬‎)+962
  • Kazakhstan (Казахстан)+7
  • Kenya+254
  • Kiribati+686
  • Kosovo+383
  • Kuwait (‫الكويت‬‎)+965
  • Kyrgyzstan (Кыргызстан)+996
  • Laos (ລາວ)+856
  • Latvia (Latvija)+371
  • Lebanon (‫لبنان‬‎)+961
  • Lesotho+266
  • Liberia+231
  • Libya (‫ليبيا‬‎)+218
  • Liechtenstein+423
  • Lithuania (Lietuva)+370
  • Luxembourg+352
  • Macau (澳門)+853
  • Macedonia (FYROM) (Македонија)+389
  • Madagascar (Madagasikara)+261
  • Malawi+265
  • Malaysia+60
  • Maldives+960
  • Mali+223
  • Malta+356
  • Marshall Islands+692
  • Martinique+596
  • Mauritania (‫موريتانيا‬‎)+222
  • Mauritius (Moris)+230
  • Mayotte+262
  • Mexico (México)+52
  • Micronesia+691
  • Moldova (Republica Moldova)+373
  • Monaco+377
  • Mongolia (Монгол)+976
  • Montenegro (Crna Gora)+382
  • Montserrat+1664
  • Morocco (‫المغرب‬‎)+212
  • Mozambique (Moçambique)+258
  • Myanmar (Burma) (မြန်မာ)+95
  • Namibia (Namibië)+264
  • Nauru+674
  • Nepal (नेपाल)+977
  • Netherlands (Nederland)+31
  • New Caledonia (Nouvelle-Calédonie)+687
  • New Zealand+64
  • Nicaragua+505
  • Niger (Nijar)+227
  • Nigeria+234
  • Niue+683
  • Norfolk Island+672
  • North Korea (조선 민주주의 인민 공화국)+850
  • Northern Mariana Islands+1670
  • Norway (Norge)+47
  • Oman (‫عُمان‬‎)+968
  • Pakistan (‫پاکستان‬‎)+92
  • Palau+680
  • Palestine (‫فلسطين‬‎)+970
  • Panama (Panamá)+507
  • Papua New Guinea+675
  • Paraguay+595
  • Peru (Perú)+51
  • Philippines+63
  • Poland (Polska)+48
  • Portugal+351
  • Puerto Rico+1
  • Qatar (‫قطر‬‎)+974
  • Réunion (La Réunion)+262
  • Romania (România)+40
  • Russia (Россия)+7
  • Rwanda+250
  • Saint Barthélemy+590
  • Saint Helena+290
  • Saint Kitts and Nevis+1869
  • Saint Lucia+1758
  • Saint Martin (Saint-Martin (partie française))+590
  • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
  • Saint Vincent and the Grenadines+1784
  • Samoa+685
  • San Marino+378
  • São Tomé and Príncipe (São Tomé e Príncipe)+239
  • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
  • Senegal (Sénégal)+221
  • Serbia (Србија)+381
  • Seychelles+248
  • Sierra Leone+232
  • Singapore+65
  • Sint Maarten+1721
  • Slovakia (Slovensko)+421
  • Slovenia (Slovenija)+386
  • Solomon Islands+677
  • Somalia (Soomaaliya)+252
  • South Africa+27
  • South Korea (대한민국)+82
  • South Sudan (‫جنوب السودان‬‎)+211
  • Spain (España)+34
  • Sri Lanka (ශ්‍රී ලංකාව)+94
  • Sudan (‫السودان‬‎)+249
  • Suriname+597
  • Svalbard and Jan Mayen+47
  • Swaziland+268
  • Sweden (Sverige)+46
  • Switzerland (Schweiz)+41
  • Syria (‫سوريا‬‎)+963
  • Taiwan (台灣)+886
  • Tajikistan+992
  • Tanzania+255
  • Thailand (ไทย)+66
  • Timor-Leste+670
  • Togo+228
  • Tokelau+690
  • Tonga+676
  • Trinidad and Tobago+1868
  • Tunisia (‫تونس‬‎)+216
  • Turkey (Türkiye)+90
  • Turkmenistan+993
  • Turks and Caicos Islands+1649
  • Tuvalu+688
  • U.S. Virgin Islands+1340
  • Uganda+256
  • Ukraine (Україна)+380
  • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
  • United Kingdom+44
  • United States+1
  • Uruguay+598
  • Uzbekistan (Oʻzbekiston)+998
  • Vanuatu+678
  • Vatican City (Città del Vaticano)+39
  • Venezuela+58
  • Vietnam (Việt Nam)+84
  • Wallis and Futuna (Wallis-et-Futuna)+681
  • Western Sahara (‫الصحراء الغربية‬‎)+212
  • Yemen (‫اليمن‬‎)+967
  • Zambia+260
  • Zimbabwe+263
  • Åland Islands+358
Captcha refresh
loader
Insights Image

Request A FREE Sample PDF PDF

Man
Mail
Captcha refresh
loader

Join Our Newsletter

Get the latest news on our products, services, discounts, and special offers delivered directly to your mailbox.

footer logo

Global Growth Insights
Office No.- B, 2nd Floor, Icon Tower, Baner-Mhalunge Road, Baner, Pune 411045, Maharashtra, India.

Useful Links

  • HOME
  • ABOUT US
  • TERMS OF SERVICE
  • PRIVACY POLICY

Our Contacts

Toll-Free Numbers:
US : +1 (855) 467-7775
UK : +44 8085 022397

Email:
 sales@globalgrowthinsights.com

Connect With Us

Twitter

footer logo

© Copyright 2024 Global Growth Insights. All Rights Reserved | Powered by Absolute Reports.
×
We use cookies.

to enhance your experience.

More info.
  • Industries
    •   Information & Technology
    •   Healthcare
    •   Machinery & Equipment
    •   Automotive & Transportation
    •   Food & Beverages
    •   Energy & Power
    •   Aerospace & Defense
    •   Agriculture
    •   Chemicals & Materials
    •   Architecture
    •   Consumer Goods
  • Blogs
  • About
  • Contact